Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
Date:6/1/2011

SAN FRANCISCO, June 1, 2011 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2011 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 7, 2011 at 10:00 a.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until July 7, 2011.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.  NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Forward-Looking StatementsThis press release contains forward-looking statements that reflect management's current views regarding Nektar's business and certain drug candidates in Nektar's pipeline.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of Nektar's drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delay, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; and (vi) certain other important risks and uncertainties set forth in Nektar's Annual Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 29, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners

(650) 575-1509
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
2. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
3. Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
5. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
6. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2010 on Tuesday, March 1, 2011, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
8. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
9. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
10. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
11. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... India , April 29, 2016 ... Pipeline Review, H1 2016" market research report that ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:4/29/2016)... , April 29, 2016 Glycotope ... expertise, today announces the appointment of Dr. Alfredo ... Zurlo is an oncologist with many years clinical experience ... biotechnology industries. His last role was at Mologen AG ... the Executive Board. Previously Dr. Zurlo held various positions ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 30, 2016 , ... Mercy College is expanding its Graduate Business Programs to ... expanding due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe ...
(Date:4/29/2016)... ... 2016 , ... Memorial Healthcare System Graduate Medical Education ... that it has received accreditation for its residency program on Physical Medicine and ... Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows the ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... Fla. (PRWEB) , ... April 29, 2016 , ... ... Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have better ... is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to ...
Breaking Medicine News(10 mins):